AFfirm™ PDCD4 Mouse Monoclonal Antibody - #BF8141
製品説明
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
折りたたみ／展開
Death up-regulated gene protein; Dug; H731; Ma3; MGC33046; MGC33047; Neoplastic transformation inhibitor; Neoplastic transformation inhibitor protein; Nuclear antigen H731; Nuclear antigen H731 like; Nuclear antigen H731 like protein; Nuclear antigen H731-like; PDCD 4; Pdcd4; PDCD4_HUMAN; Programmed cell death 4; programmed cell death 4 (neoplastic transformation inhibitor); Programmed cell death protein 4; Protein 197/15a; Protein MA-3; Tis; Topoisomerase-inhibitor suppressed protein;
免疫原
Up-regulated in proliferative cells. Highly expressed in epithelial cells of the mammary gland. Reduced expression in lung cancer and colon carcinoma.
- Q53EL6 PDCD4_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MDVENEQILNVNPADPDNLSDSLFSGDEENAGTEEIKNEINGNWISASSINEARINAKAKRRLRKNSSRDSGRGDSVSDSGSDALRSGLTVPTSPKGRLLDRRSRSGKGRGLPKKGGAGGKGVWGTPGQVYDVEEVDVKDPNYDDDQENCVYETVVLPLDERAFEKTLTPIIQEYFEHGDTNEVAEMLRDLNLGEMKSGVPVLAVSLALEGKASHREMTSKLLSDLCGTVMSTTDVEKSFDKLLKDLPELALDTPRAPQLVGQFIARAVGDGILCNTYIDSYKGTVDCVQARAALDKATVLLSMSKGGKRKDSVWGSGGGQQSVNHLVKEIDMLLKEYLLSGDISEAEHCLKELEVPHFHHELVYEAIIMVLESTGESTFKMILDLLKSLWKSSTITVDQMKRGYERIYNEIPDINLDVPHSYSVLERFVEECFQAGIISKQLRDLCPSRGRKRFVSEGDGGRLKPESY
PTMs - Q53EL6 基板として
| Site | PTM Type | Enzyme | Source |
|---|---|---|---|
| M1 | Acetylation | Uniprot | |
| S20 | Phosphorylation | Uniprot | |
| S22 | Phosphorylation | Uniprot | |
| S25 | Phosphorylation | Uniprot | |
| S46 | Phosphorylation | Uniprot | |
| K58 | Ubiquitination | Uniprot | |
| K60 | Ubiquitination | Uniprot | |
| S67 | Phosphorylation | P31749 (AKT1) , P23443 (RPS6KB1) , Q9UBS0 (RPS6KB2) | Uniprot |
| S68 | Phosphorylation | Uniprot | |
| S71 | Phosphorylation | Uniprot | |
| R73 | Methylation | Uniprot | |
| S76 | Phosphorylation | Uniprot | |
| S78 | Phosphorylation | Uniprot | |
| S80 | Phosphorylation | Uniprot | |
| S82 | Phosphorylation | Uniprot | |
| S87 | Phosphorylation | Uniprot | |
| T90 | Phosphorylation | Uniprot | |
| T93 | Phosphorylation | Uniprot | |
| S94 | Phosphorylation | Uniprot | |
| K96 | Ubiquitination | Uniprot | |
| K121 | Ubiquitination | Uniprot | |
| T126 | Phosphorylation | Uniprot | |
| Y131 | Phosphorylation | Uniprot | |
| Y143 | Phosphorylation | Uniprot | |
| Y152 | Phosphorylation | Uniprot | |
| K166 | Ubiquitination | Uniprot | |
| K212 | Ubiquitination | Uniprot | |
| K238 | Ubiquitination | Uniprot | |
| K242 | Ubiquitination | Uniprot | |
| K245 | Ubiquitination | Uniprot | |
| T254 | Phosphorylation | Uniprot | |
| R267 | Methylation | Uniprot | |
| K283 | Ubiquitination | Uniprot | |
| K297 | Ubiquitination | Uniprot | |
| T299 | Phosphorylation | Uniprot | |
| S303 | Phosphorylation | Uniprot | |
| K306 | Ubiquitination | Uniprot | |
| K311 | Ubiquitination | Uniprot | |
| S313 | Phosphorylation | Uniprot | |
| S317 | Phosphorylation | Uniprot | |
| S323 | Phosphorylation | Uniprot | |
| S345 | Phosphorylation | Uniprot | |
| K392 | Ubiquitination | Uniprot | |
| K402 | Ubiquitination | Uniprot | |
| Y405 | Phosphorylation | Uniprot | |
| S440 | Phosphorylation | Uniprot | |
| S457 | Phosphorylation | P31749 (AKT1) | Uniprot |
| K465 | Sumoylation | Uniprot | |
| S468 | Phosphorylation | Uniprot |
研究背景
Inhibits translation initiation and cap-dependent translation. May excert its function by hindering the interaction between EIF4A1 and EIF4G. Inhibits the helicase activity of EIF4A. Modulates the activation of JUN kinase. Down-regulates the expression of MAP4K1, thus inhibiting events important in driving invasion, namely, MAPK85 activation and consequent JUN-dependent transcription. May play a role in apoptosis. Tumor suppressor. Inhibits tumor promoter-induced neoplastic transformation. Binds RNA (By similarity).
Polyubiquitinated, leading to its proteasomal degradation. Rapidly degraded in response to mitogens. Phosphorylation of the phosphodegron promotes interaction with BTRC and proteasomal degradation.
Phosphorylated at Ser-67 by RPS6KB1 in response to mitogens; phosphorylation promotes proteasomal degradation of PDCD4.
Nucleus. Cytoplasm.
Note: Shuttles between the nucleus and cytoplasm (By similarity). Predominantly nuclear under normal growth conditions, and when phosphorylated at Ser-457 (PubMed:16357133).
Up-regulated in proliferative cells. Highly expressed in epithelial cells of the mammary gland. Reduced expression in lung cancer and colon carcinoma.
Interacts (via MI domains) with EIF4A2 (By similarity). Interacts (via MI domains) with EIF4A1 (via N-terminal domain). Heterotrimer with EIF4A1; one molecule of PDCD4 binds two molecules of EIF4A1. Interacts with EIF4G1. May form a complex with EIF4A1 and EIF4G1. The interaction between PDCD4 and EIF4A1 interferes with the interaction between EIF4A1 and EIF4G. When phosphorylated, interacts with BTRC and FBXW11.
Binds EIF4A1 via both MI domains.
Belongs to the PDCD4 family.
研究領域
· Human Diseases > Cancers: Overview > Proteoglycans in cancer.
· Human Diseases > Cancers: Overview > MicroRNAs in cancer.
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.